Divi's Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹3,676 crore and net profit of ₹1,127 crore for the September 2026 quarter.
Divi's Laboratories (NSE: DIVISLAB) closed at ₹11,180.50 on 20 Nov 2026, up 73.0% over the past year. Its market capitalisation is ₹2,96,807 crore and it trades at 86.9 times earnings.
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.